Yangtze River will win $3 billion in oral hypoglycemic drugs!

Recently, Guangzhou Hairui Pharmaceuticals of Yangtze River Pharmaceutical Group entered the administrative examination and approval stage with imitation of Sitagliptin phosphate tablets submitted for production in Category 4
.
The product is developed by Merck and has global sales of more than 3 billion U.

Data show that sitagliptin phosphate tablets are a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor, a new type of oral anti-hyperglycemic drug based on the mechanism of incretin hormone.
Used to improve blood sugar control in patients with type 2 diabetes
.

Sales of sitagliptin tablets in Chinese public medical institutions and physical pharmacies in Chinese cities

Source: Mi Nei Net Database

Sitagliptin phosphate tablets were developed by Merck, with global sales exceeding US$3 billion in 2020
.
Meinenet data shows that in recent years, the sales of sitagliptin tablets in urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions), and sitagliptin tablets in physical pharmacies in cities in China have grown rapidly in recent years.

Source: One-click search on Mi Nei.
com

Sitagliptin phosphate tablets have 5 manufacturers.
Among them, Guangdong Dongyang Sunshine Pharmaceutical, CSPC Ouyi Pharmaceutical, Zhejiang Pharmaceutical Xinchang Pharmaceutical Factory, and Chia Tai Tianqing Pharmaceutical Group have 4 domestic pharmaceutical companies with imitations of 4 types.
Approved, it is deemed to have been reviewed
.
At present, the product has 11 companies including Qilu Pharmaceutical (Hainan), Zhejiang Huahai Pharmaceutical, Nanjing Zhengda Tianqing Pharmaceutical, and Sichuan Kelun Pharmaceutical who have submitted listing applications for review and approval

Source: official website of the State Food and Drug Administration, Mi Nei.